vs
Encompass Health Corp（EHC）とRollins, Inc.（ROL）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $906.4M、Rollins, Inc.の約1.7倍）。Rollins, Inc.の純利益率が高く（11.9% vs 9.5%、差は2.4%）。Rollins, Inc.の前年同期比売上増加率が高い（10.2% vs 9.9%）。Encompass Health Corpの直近四半期フリーキャッシュフローが多い（$116.7M vs $111.2M）。過去8四半期でEncompass Health Corpの売上複合成長率が高い（8.3% vs 0.8%）
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
Rollins, Inc.は北米を代表する害虫駆除企業で、一般住宅向け及び商業施設向けのサービスを提供しています。完全子会社のOrkin、HomeTeam Pest Defenseなどを通じて北米、イギリスをはじめ世界各国で事業を展開し、害虫駆除分野で高いブランド力と市場シェアを有しています。
EHC vs ROL — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $1.5B | $906.4M |
| 純利益 | $146.1M | $107.8M |
| 粗利率 | — | — |
| 営業利益率 | 16.7% | 16.1% |
| 純利益率 | 9.5% | 11.9% |
| 売上前年比 | 9.9% | 10.2% |
| 純利益前年比 | 20.8% | 2.5% |
| EPS（希薄化後） | $1.43 | $0.22 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.5B | $912.9M | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.5B | $999.5M | ||
| Q1 25 | $1.5B | $822.5M | ||
| Q4 24 | $1.4B | $832.2M | ||
| Q3 24 | $1.4B | $916.3M | ||
| Q2 24 | $1.3B | $891.9M |
| Q1 26 | — | $107.8M | ||
| Q4 25 | $146.1M | $116.4M | ||
| Q3 25 | $126.5M | $163.5M | ||
| Q2 25 | $142.1M | $141.5M | ||
| Q1 25 | $151.5M | $105.2M | ||
| Q4 24 | $120.9M | $105.7M | ||
| Q3 24 | $108.2M | $136.9M | ||
| Q2 24 | $114.1M | $129.4M |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 16.7% | 17.5% | ||
| Q3 25 | 14.9% | 21.9% | ||
| Q2 25 | 16.2% | 19.8% | ||
| Q1 25 | 16.4% | 17.3% | ||
| Q4 24 | 14.3% | 18.1% | ||
| Q3 24 | 13.6% | 20.9% | ||
| Q2 24 | 14.3% | 20.4% |
| Q1 26 | — | 11.9% | ||
| Q4 25 | 9.5% | 12.8% | ||
| Q3 25 | 8.6% | 15.9% | ||
| Q2 25 | 9.7% | 14.2% | ||
| Q1 25 | 10.4% | 12.8% | ||
| Q4 24 | 8.6% | 12.7% | ||
| Q3 24 | 8.0% | 14.9% | ||
| Q2 24 | 8.8% | 14.5% |
| Q1 26 | — | $0.22 | ||
| Q4 25 | $1.43 | $0.24 | ||
| Q3 25 | $1.24 | $0.34 | ||
| Q2 25 | $1.39 | $0.29 | ||
| Q1 25 | $1.48 | $0.22 | ||
| Q4 24 | $1.18 | $0.22 | ||
| Q3 24 | $1.06 | $0.28 | ||
| Q2 24 | $1.12 | $0.27 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $72.2M | $116.5M |
| 総負債低いほど良い | $2.4B | $650.6M |
| 株主資本純資産 | $2.4B | $1.4B |
| 総資産 | $7.1B | $3.2B |
| 負債/資本比率低いほどレバレッジが低い | 1.00× | 0.47× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $116.5M | ||
| Q4 25 | $72.2M | $100.0M | ||
| Q3 25 | $48.7M | $127.4M | ||
| Q2 25 | $99.1M | $123.0M | ||
| Q1 25 | $95.8M | $201.2M | ||
| Q4 24 | $85.4M | $89.6M | ||
| Q3 24 | $147.8M | $95.3M | ||
| Q2 24 | $154.4M | $106.7M |
| Q1 26 | — | $650.6M | ||
| Q4 25 | $2.4B | $486.1M | ||
| Q3 25 | $2.4B | $485.7M | ||
| Q2 25 | $2.3B | $485.3M | ||
| Q1 25 | $2.3B | $485.5M | ||
| Q4 24 | $2.4B | $395.3M | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.7B | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.4B | $1.5B | ||
| Q2 25 | $2.3B | $1.4B | ||
| Q1 25 | $2.2B | $1.4B | ||
| Q4 24 | $2.1B | $1.3B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $1.8B | $1.2B |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $7.1B | $3.1B | ||
| Q3 25 | $6.9B | $3.2B | ||
| Q2 25 | $6.8B | $3.2B | ||
| Q1 25 | $6.6B | $2.9B | ||
| Q4 24 | $6.5B | $2.8B | ||
| Q3 24 | $6.5B | $2.8B | ||
| Q2 24 | $6.4B | $2.8B |
| Q1 26 | — | 0.47× | ||
| Q4 25 | 1.00× | 0.35× | ||
| Q3 25 | 1.01× | 0.32× | ||
| Q2 25 | 1.02× | 0.34× | ||
| Q1 25 | 1.08× | 0.36× | ||
| Q4 24 | 1.14× | 0.30× | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.46× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $346.0M | $118.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $116.7M | $111.2M |
| FCFマージンFCF / 売上 | 7.6% | 12.3% |
| 設備投資強度設備投資 / 売上 | 14.8% | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 2.37× | 1.10× |
| 直近12ヶ月FCF直近4四半期 | $439.2M | $621.1M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $118.4M | ||
| Q4 25 | $346.0M | $164.7M | ||
| Q3 25 | $270.8M | $191.3M | ||
| Q2 25 | $270.2M | $175.1M | ||
| Q1 25 | $288.6M | $146.9M | ||
| Q4 24 | $278.8M | $188.2M | ||
| Q3 24 | $267.8M | $146.9M | ||
| Q2 24 | $217.4M | $145.1M |
| Q1 26 | — | $111.2M | ||
| Q4 25 | $116.7M | $159.0M | ||
| Q3 25 | $83.7M | $182.8M | ||
| Q2 25 | $113.3M | $168.0M | ||
| Q1 25 | $125.5M | $140.1M | ||
| Q4 24 | $80.1M | $184.0M | ||
| Q3 24 | $120.3M | $139.4M | ||
| Q2 24 | $60.5M | $136.4M |
| Q1 26 | — | 12.3% | ||
| Q4 25 | 7.6% | 17.4% | ||
| Q3 25 | 5.7% | 17.8% | ||
| Q2 25 | 7.8% | 16.8% | ||
| Q1 25 | 8.6% | 17.0% | ||
| Q4 24 | 5.7% | 22.1% | ||
| Q3 24 | 8.9% | 15.2% | ||
| Q2 24 | 4.6% | 15.3% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 14.8% | 0.6% | ||
| Q3 25 | 12.7% | 0.8% | ||
| Q2 25 | 10.8% | 0.7% | ||
| Q1 25 | 11.2% | 0.8% | ||
| Q4 24 | 14.1% | 0.5% | ||
| Q3 24 | 10.9% | 0.8% | ||
| Q2 24 | 12.1% | 1.0% |
| Q1 26 | — | 1.10× | ||
| Q4 25 | 2.37× | 1.41× | ||
| Q3 25 | 2.14× | 1.17× | ||
| Q2 25 | 1.90× | 1.24× | ||
| Q1 25 | 1.90× | 1.40× | ||
| Q4 24 | 2.31× | 1.78× | ||
| Q3 24 | 2.48× | 1.07× | ||
| Q2 24 | 1.91× | 1.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
ROL
セグメントデータなし
